PMGC subsidiary Northstrive licenses Yuva Biosciences' AI platform for obesity and cardiometabolic drugs

PMGC Holdings Inc.

Northstrive (PMGC subsidiary, ticker ELAB) signs exclusive worldwide license for therapies in cardiac diseases and obesity.
YuvaBio to use its AI platform MitoNova to identify small molecule candidates targeting mitochondrial health.
Upfront fee, development milestone payments, and tiered royalties on net sales; no specific dollar amounts disclosed.
Multi-phase program includes in silico modeling, virtual screening, and wet-lab validation to shortlist candidates.
Agreement covers multi-year term; Northstrive may terminate for convenience with early termination fee.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.